Skip to main content
Fanli Digital Technology Co., Ltd logo

Fanli Digital Technology Co., Ltd — Investor Relations & Filings

Ticker · 600228 ISIN · CNE000000Y78 Shanghai Stock Exchange Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 2,251 across all filing types
Latest filing 2020-03-25 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600228

About Fanli Digital Technology Co., Ltd

https://corp.fanli.com/

Fanli Digital Technology Co., Ltd. provides e-commerce integration and digital marketing services. The company operates a comprehensive platform that connects consumers with various online retail ecosystems through value-added services such as cash-back rewards, discount coupons, and promotional insights. Its core business model focuses on performance-based marketing, utilizing data-driven strategies to facilitate sales conversions for brand partners. Key offerings include brand promotion, user loyalty management, and targeted advertising solutions. By integrating diverse shopping channels into a single interface, the company optimizes the consumer purchasing journey and provides brands with scalable traffic acquisition tools. The platform serves as a strategic intermediary, leveraging user behavioral data to enhance marketing efficiency and provide measurable returns for merchants while delivering cost savings to a broad user base.

Recent filings

Filing Released Lang Actions
关于重大资产重组网络媒体说明会召开情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement and transcript of a "重大资产重组网络媒体说明会" (Major Asset Restructuring Online Media Briefing) held by 江西昌九生物化工股份有限公司. It includes extensive descriptions of the asset restructuring plan, the involved parties, the business rationale, and the Q&A session with media and investors. The content focuses on explaining the major asset restructuring, including issuance of shares, acquisition, and fundraising, with detailed financial and operational information about the target company. This is not a full annual or quarterly report, nor is it a simple announcement or certification. It is a detailed disclosure related to a major asset restructuring event, which fits the category of Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive information about the transaction, financing, and restructuring, not just an announcement or invitation. Therefore, the best classification is CAP (Capital/Financing Update).
2020-03-25 Chinese
上海市方达律师事务所关于江西昌九生物化工股份有限公司召开重大资产重组媒体说明会之法律意见书
M&A Activity Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening of a major asset restructuring media briefing by Jiangxi Changjiu Bio-chemical Co., Ltd. It discusses the notification, procedures, participants, and information disclosure related to the media briefing. The document references the media briefing and related announcements but does not contain financial statements or detailed financial data. It is not an annual report, interim report, earnings release, or any direct financial report. Instead, it is a legal opinion related to a media briefing about a major asset restructuring, which aligns with the category of M&A Activity (TAR). The document is not a simple announcement or certification but a substantive legal opinion on the media briefing for a major asset restructuring, which is part of merger and acquisition activities.
2020-03-25 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by Jiangxi Changjiu Biochemical Co., Ltd. It discusses the stock price movements over specific dates, the company's self-inspection, ongoing major asset restructuring plans, related risks, and statements from the board. The document does not contain financial statements or detailed financial data but serves as a regulatory disclosure about unusual stock price movements and related corporate events. It is not an annual report, earnings release, or financial supplement. It is also not a report publication announcement since it contains substantive information about the stock price abnormality and related risks. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2020-03-23 Chinese
杭州同美股权投资基金合伙企业（有限合伙）《关于江西昌九生物化工股份有限公司股票交易异常波动的询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations of Jiangxi Changjiu Bio-chemical Co., Ltd. It states that no undisclosed major information or stock trading occurred during the period of abnormal fluctuations. The document is short (445 characters) and is a formal reply to a regulatory inquiry rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or audit information. It is best classified as a Regulatory Filing (RNS) because it is a compliance-related response to a regulatory inquiry about stock trading activity.
2020-03-23 Chinese
江西昌九集团有限公司《关于江西昌九生物化工股份有限公司股票交易异常波动的询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a formal response letter to an inquiry about abnormal stock trading fluctuations. It addresses the company's disclosure status regarding significant corporate actions and confirms no insider trading during the period. The content is a regulatory communication related to stock trading and disclosure compliance, not a financial report, management change, or other specific filing types. The document is short (420 characters) and serves as a regulatory reply rather than a report or announcement. Therefore, it fits best under Regulatory Filings (RNS).
2020-03-23 Chinese
北京市文化中心建设发展基金管理有限公司《关于江西昌九生物化工股份有限公司股票交易异常波动的询证函》的回函
Regulatory Filings Classification · 95% confidence The document is a response letter to an inquiry about abnormal stock trading fluctuations of Jiangxi Changjiu Bio-chemical Co., Ltd. It states that no undisclosed major information or stock trading occurred during the period in question. The document is short (434 characters) and is a formal reply to a regulatory inquiry rather than a financial report or announcement of financial results. It does not contain financial data, management changes, voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a compliance-related communication responding to a regulatory inquiry about stock trading activity.
2020-03-23 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.